NeuroBytes: New Treatments in Autoimmune Myasthenia Gravis
Course Description
Myasthenia Gravis is an autoimmune neuromuscular junction disorder. For decades it has been treated with acetylcholinesterase inhibitors, steroids and old chronic immunotherapies. Even with multiple agents, not all patients achieve satisfactory improvement in the symptoms. In last few years, FDA has approved newer therapies that have different mechanisms of action as they have shown reasonable benefit in myasthenic patients with positive acetylcholine receptor antibodies. We have prepared this video with aim to provide insight into these newer therapies for seropositive myasthenia gravis, their indications, dosing and their adverse effects.
Learning Objectives
As a result of this program the learner will be able to:
- Identify and describe the newest medications of myasthenia gravis and understand when to apply them to treat patients of myasthenia.
Date of Release
October 31, 2023
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved. See complete
Terms of Use.
Faculty & Disclosures
VARUN JAIN, MD, MBBS
Fellow Neuromuscular Medicine, Neurology
University of Florida
Gainesville, FL
*Dr. Jain has nothing to disclose.
Editor
Reviewer
Voiceover Artist
Fellow Neuromuscular Medicine, Neurology
University of Florida
Gainesville, FL
*Dr. Jain has nothing to disclose.
Editor
MIGUEL CHUQUILIN ARISTA, MD, FAAN
Neurologic Consultant
Tallahassee Memorial Hospital
Tallahassee, FL
*Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item writer with American Academy of Neurology. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item Writer with American Academy of Neurology. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item Writer with American Academy of Neurology. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item reviewer with National Board of Medical Examiners. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Southeast regional advisory board with Argenx. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Focus group with Alexion. Dr. Chuquilin Arista has received personal compensation in the range of $0-$499 for serving as a Speaker with Periodic Paralysis Association.
Reviewer
ZACHARY LONDON MD, FAAN
Professor
University of Michigan
Ann Arbor, Michigan
*Dr. London has nothing to disclose.
Voiceover Artist
Brooke Bloom, DO, MS
Chief Resident, PGY-4
Department of Neurology
University of Massachusetts Medical School
Worcester, MA
*Dr. Bloom has nothing to disclose.
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, Manager, eLearning
Minneapolis, MN
*Mr. Rook has nothing to disclose.
Sulia Altenberg, eLearning Coordinator
Minneapolis, MN
*Ms. Altenberg has nothing to disclose.
*Relationship Disclosure